OVID

1.57

4.85% -0.08

Dopo l'orario di chiusura: 1.58 0.01 +0.64%

Ovid Therapeutics Inc (OVID)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.65

Aprire:

$1.64

Volume 24 ore:

1.94M

Relative Volume:

0.62

Capitalizzazione di mercato:

$111.64M

Reddito:

$391.70K

Utile/perdita netta:

$-52.34M

Rapporto P/E:

-2.0933

EPS:

-0.75

Flusso di cassa netto:

$-45.92M

1 W Prestazione:

-9.77%

1M Prestazione:

+37.72%

6M Prestazione:

+479.55%

1 anno Prestazione:

+33.05%

Intervallo 1D:

$1.56

$1.72

Intervallo di 1 settimana:

$1.5332

$1.84

Portata 52W:

$0.2425

$2.01

Ovid Therapeutics Inc Stock (OVID) Company Profile

Nome

Ovid Therapeutics Inc

Settore

Healthcare (1140)

Industria

Biotechnology (637)

Telefono

212-776-4381

Indirizzo

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Dipendente

Cinguettio

@OvidRx

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

OVID's Discussions on Twitter

Confronta OVID con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OVID Ovid Therapeutics Inc	1.57	124.44M	391.70K	-52.34M	-45.92M	-0.75
VRTX Vertex Pharmaceuticals Inc	408.61	105.69B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	481.07	61.52B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	569.17	60.69B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	837.28	50.05B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	318.02	35.25B	4.56B	-176.77M	225.30M	-1.7177

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-09	Iniziato	Oppenheimer	Outperform
2025-08-08	Ripresa	B. Riley Securities	Buy
2024-06-18	Downgrade	Oppenheimer	Outperform → Perform
2024-04-30	Iniziato	B. Riley Securities	Buy
2024-04-29	Iniziato	H.C. Wainwright	Buy
2024-04-05	Iniziato	Wedbush	Outperform
2023-12-21	Iniziato	BTIG Research	Buy
2023-10-13	Iniziato	Oppenheimer	Outperform
2021-04-20	Downgrade	Cantor Fitzgerald	Buy → Neutral
2021-03-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-12-02	Downgrade	Citigroup	Buy → Neutral
2020-12-02	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-04	Iniziato	RBC Capital Mkts	Outperform
2018-04-20	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Ovid Therapeutics Inc Borsa (OVID) Ultime notizie

Oct 16, 2025

Market reaction to Ovid Therapeutics Inc.’s recent news2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com

Oct 16, 2025

Oct 15, 2025

Will Ovid Therapeutics Inc. (1OT) stock deliver compounding returnsShare Buyback & Low Drawdown Momentum Ideas - newser.com

Oct 15, 2025

Oct 14, 2025

Is Ovid Therapeutics Inc. showing signs of accumulationWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - newser.com

Oct 14, 2025

Oct 13, 2025

Is a relief rally coming for Ovid Therapeutics Inc. holdersPortfolio Update Summary & AI Enhanced Trading Signals - newser.com

Oct 13, 2025

Combining machine learning predictions for Ovid Therapeutics Inc.2025 Volatility Report & Consistent Growth Stock Picks - newser.com

Oct 13, 2025

Oct 12, 2025

Is Ovid Therapeutics Inc. (1OT) stock protected from inflationMarket Performance Summary & Verified Technical Signals - newser.com

Oct 12, 2025

Oct 10, 2025

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - The Globe and Mail

Oct 10, 2025

Oppenheimer Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat

Oct 10, 2025

Ovid Therapeutics' (OVID) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025

Will Ovid Therapeutics Inc. benefit from macro trendsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com

Oct 10, 2025

Real time pattern detection on Ovid Therapeutics Inc. stock2025 Bull vs Bear & Short-Term Trading Alerts - newser.com

Oct 10, 2025

Ovid Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Exceptional Trading Strategies - earlytimes.in

Oct 10, 2025

Oct 09, 2025

Ovid spikes as Wedbush moves to Outperform on lead asset - MSN

Oct 09, 2025

Ovid Therapeutics (OVID) Surges on Positive Analyst Rating - GuruFocus

Oct 09, 2025

Ovid Therapeutics' OV329 Shows Promise as Epilepsy Treatment, Oppenheimer Says - MarketScreener

Oct 09, 2025

Technical signs of recovery in Ovid Therapeutics Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com

Oct 09, 2025

What data driven models say about Ovid Therapeutics Inc.’s futureWeekly Risk Report & High Yield Equity Trading Tips - newser.com

Oct 09, 2025

What drives PSP Swiss Property AG Common Stock P7S0 stock priceCapital Gains Strategies & Follow Top Performers in the Community - earlytimes.in

Oct 09, 2025

Is Ovid Therapeutics Inc. (1OT) stock vulnerable to rate hikesJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com

Oct 09, 2025

Detecting price anomalies in Ovid Therapeutics Inc. with AITrade Volume Report & Real-Time Buy Zone Alerts - newser.com

Oct 09, 2025

Tools to assess Ovid Therapeutics Inc.’s risk profileEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com

Oct 09, 2025

Oct 07, 2025

Hudson Yards seizure drug company raises $81M after cutting expenses - Crain's New York Business

Oct 07, 2025

What analysts say about Ovid Therapeutics Inc 1OT stockStock Rotation Strategies & Minimal Capital Investment - earlytimes.in

Oct 07, 2025

Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing - Sahm

Oct 07, 2025

Oct 06, 2025

Ovid Therapeutics Hits New 52-Week High at $2.01, Marking Significant Milestone - Markets Mojo

Oct 06, 2025